United States relaxes rules for biotech crops
By Erik Stokstad,
Science
| 05. 18. 2020
New regulations focus on traits, not the technology used to create them. An engineered plant won’t be regulated if it contains minor changes that could have been made through traditional breeding.
Photo by Erwan Hesry via Unsplash.com
A major change to U.S. regulation of biotech will exempt some gene-edited plants from government oversight. The new policy, published in the Federal Register today, also calls for automatic approval of variations of established kinds of genetically modified (GM) crops, easing their path to market.
Industry groups are welcoming the new rule, whereas opponents are decrying the reduction of government oversight.
“The main good thing is that it will allow certain aspects of gene editing to move forward,” says Kent Bradford, a plant geneticist at the University of California, Davis. If researchers use gene editing to design a plant that could have been bred conventionally, the new plant will be exempt from regulation. But anything else—such as moving a gene between species or rewiring metabolism—will still require a regulatory review.
The gist of the shift is that the U.S. Department of Agriculture’s (USDA’s) Animal and Plant Health Inspection Service (APHIS) will now focus on new traits themselves rather than the technology used to create them, a change of approach that plant scientists have long...
Related Articles
GeneWatch UK has prepared a briefing on the genetic modification of nature for the International Union for Conservation of Nature (IUCN) Congress in October 2025
The upcoming Congress claims to be “where the world comes together to set priorities and drive conservation and sustainable development action.” A major concern for those on the outside is that the Congress may advance plans to develop and encourage the use of synthetic biology in nature conservation. This could at first glance sound like...
By Aaron Ginn, The Washington Post | 09.12.2025
Earlier this year, I had dinner in D.C. with Jensen Huang, the president and chief executive of Nvidia. At one point, he said something that struck me: “Why is everyone here so negative?”
He wasn’t referring to the economy...
By Roni Caryn Rabin, The New York Times | 08.25.2025
Scientists have dreamed for centuries about using animal organs to treat ailing humans. In recent years, those efforts have begun to bear fruit: Researchers have begun transplanting the hearts and kidneys of genetically modified pigs into patients, with varying degrees...
The Center for Genetics and Society is delighted to recommend the current edition of GMWatch Review – Number 589. UK-based GMWatch, a long-standing ally, was founded in 1998 by Jonathan Matthews as an independent organization seeking to counter the enormous corporate political power and propaganda of the GMO industry and its supporters. Matthews and Claire Robinson are its directors and managing editors.
CGS works to ensure that social justice, equity, human rights, and democratic governance are front...